Merck trades at a low P/E with strong financials, Keytruda growth, and a solid 3.9% yield, while its pipeline offsets future risks. Read why MRK stock is a buy.

M&A deals announced worldwide in July included a rail merger, which is the largest transaction in the past 12 months based on ...

MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected ...

LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported second quarter 2025 financial and ...

Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s ...